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Neurofibrillary tangles advance from layer II of
the entorhinal cortex (EC-II) toward limbic and asso-
ciation cortices as Alzheimer’s disease evolves.
However, themechanism involved in this hierarchical
pattern of disease progression is unknown. We
describe a transgenic mouse model in which overex-
pression of human tau P301L is restricted to EC-II.
Tau pathology progresses from EC transgene-ex-
pressing neurons to neurons without detectable
transgene expression, first to EC neighboring cells,
followed by propagation to neurons downstream in
the synaptic circuit such as the dentate gyrus, CA
fields of the hippocampus, and cingulate cortex.
Human tau protein spreads to these regions and
coaggregates with endogenous mouse tau. With
age, synaptic degeneration occurs in the entorhinal
target zone and EC neurons are lost. These data
suggest that a sequence of progressive misfolding
of tau proteins, circuit-based transfer to new cell
populations, and deafferentation induced degenera-
tion are part of a process of tau-induced neurode-
generation.
INTRODUCTION
It has been known for more than 25 years that neurofibrillary
tangles have a hierarchical pattern of accumulation reflecting
selective vulnerability of neuronal populations in the Alzheimer’s
disease (AD) brain, initially affecting the large projection neurons
that connect memory-related neural systems (Braak and Braak,
1991; Hyman et al., 1984). The first neurons to be affected are
in layer II of the entorhinal cortex (EC), the neurons that give riseto the perforant pathway, the single major projection linking the
cerebral cortex with the hippocampus (Go´mez-Isla et al., 1996;
Hyman et al., 1987). Over the years, a ‘‘march’’ of lesions appears
to propagate across limbic and association cortices, creating
a pattern so consistent as to be incorporated into criteria for
the neuropathological diagnosis of the illness (Hyman and Troja-
nowski, 1997). Selective loss of these neurons is believed to
contribute to the defects in memory and higher-order cognitive
functions in AD due to disconnection and deafferentation of crit-
ical neural circuits (Delacourte et al., 1999; Hyman et al., 1990).
Despite recognition of the patterns of anatomical connectivity
that link vulnerable neurons, there is no clear understanding of
the mechanism of disease progression. To create a model of
the earliest point in the neurodegenerative cascade of AD, we
generated a transgenic mouse model in which a mutant form
of the microtubule binding protein tau (MAPT) (P301L) linked to
tangle formation in frontotemporal dementia is expressed selec-
tively in a fraction of the neurons of layer II of the EC (EC-II).
The EC is the predominant cortical input and output network
of the hippocampal formation. These connections are layer
specific. The superficial layers provide neuronal projections to
the dentate gyrus in a powerful projection referred to as the per-
forant pathway (Witter, 2007). In the mouse, layer II of the EC
projects directly to the outer two-thirds of the molecular layer
of the dentate gyrus, where it connects to dendrites from the
granule cells of the dentate gyrus (Hjorth-Simonsen and Jeune,
1972; Steward, 1976). The major projection patterns are exqui-
sitely specific, with lateral EC (LEC) projecting to the outer third
of the dentate molecular layer and the medial EC projecting to
the middle third. Smaller projections provide direct EC-hippo-
campal and EC cortical connections as well. The superficial
layers of EC receive output from pre- and parasubiculum, while
the deeper layers—layers IV, V, and VI—receive output from
hippocampus (Canto et al., 2008).
With this transgenic mouse model, we tested the hypothesis
that tau pathology would evolve in the same predictable pattern
as the neuropathological development of AD. The results showNeuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc. 685
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Propagation of Tau Pathology in a Model of ADdramatic ‘‘spread’’ of pathological tau deposits from the neurons
initially expressing human tau MAPT messenger RNA (mRNA)
(referred to here as tau or htau mRNA) to populations of neurons
without detectable transgene expression, leading to coaggrega-
tion of human tau and endogenousmouse tau in neurons without
detectable levels of human tau mRNA transgene. These data
support the idea that local tau aggregation can be transmitted
from neuron to neuron, and may help explain the anatomical
patterns of tangle accumulation in AD, supporting the hypothesis
that circuit-based patterns of neurodegeneration play an impor-
tant role in the progression of tau pathology.
RESULTS
Restricted Transgene Expression and Age-Dependent
Pathology in the EC of rTgTauEC Mice
We generated a mouse line that reversibly expresses human
variant tau P301L primarily in EC-II, the rTgTauEC mouse (Fig-
ure 1A). We took advantage of a mouse line in which expression
of a tet transactivator transgene is under control of the neuropsin
gene promoter (Yasuda and Mayford, 2006). This line was
crossed with the Tg(tetO-tauP301L)4510 line that only expresses
human tau carrying the P301L frontotemporal dementia muta-
tion in the presence of a tet transactivator (Santacruz et al.,
2005). Human tau expression in bigenic rTgTauECmice is limited
largely to the superficial layers of medial EC and the closely
related pre- and parasubicular cortices (Figures 1B and 1C).
We assessed the expression of the human tau transgene in
this model by in situ hybridization. We observed intense expres-
sion as early as 3 months of age in a subset of neurons in the
medial EC (MEC) and pre- and parasubiculum (Figure 1C). The
positive neurons in the MEC were detected prominently in layer
II, although rare positive neuronswere observed in layer III, espe-
cially in the area adjacent to the parasubiculum. A few rare
neurons in the granular layer and the hilum of the dentate gyrus
(DG) showed some transgene expression in accord with obser-
vations in the parental line (Yasuda and Mayford, 2006), as well
as very rare neurons in the CA1, CA3, lateral amygdaloid
nucleus, and superficial cortical areas.
Immunohistochemistry using the 5A6 antibody (courtesy of
Dr.G.V. Johnson,UniversityofRochester), amonoclonal antibody
raised against the longest form of recombinant human tau which
recognizes an epitope between amino acids 19 and 46 (Johnson
et al., 1997), confirmed strong expression of tau protein in super-
ficial layers of the MEC and parasubiculum in rTgTauEC mice at
3 months of age compared to a control brain (Figure 1D). Higher
magnification of the EC and DG area showed transgene expres-
sion restricted to the EC, where there is diffuse axonal staining,
and to the axonal terminals in the middle molecular layer of DG,
which receivesaxonsoriginating in theMEC.Thisfinding indicates
that the human tau is transported through axons of the MEC to
their terminals in the molecular layer of DG (Figure 1D, middle
panels). Immunohistochemistry and western blot analysis of
Tg(tetO-tauP301L) tau mice brains revealed no detectable levels
of human tau protein expression (Figures S1A and S1B, respec-
tively, available online). Quantitative PCR (qPCR) revealed <2%
of rTgTauEC levels of htau mRNA in the parental tauP301L line
without transactivator within the noise of the assay (Figure S1C).686 Neuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc.Human tau expression in theMEC results in an age-dependent
accumulation of tau pathology in transgene expressing neurons.
The normal axonal distribution of human tau (Figure 1D) is lost
and the protein accumulates in the EC cell bodies. The first
sign of tau pathology was detected at 3 months of age with
Alz50 staining, an early indicator of tau misfolding, in the projec-
tion input zone of MEC, corresponding to the middle third of
the molecular layer of the DG (Figure 1E, left most panel), while
the inner and outer layers were nonreactive (for highermagnifica-
tion, see Figure S2). This axonal staining preceded Alz50 staining
in the MEC neuronal soma, where Alz50-positive tau was first
detected at 6 months of age (Figure 1E, second left panel).
From 6 months, a slow progression of tau epitopes in the
soma of MEC neurons toward later stages of pathology was
observed,marked by the presence of PHF1 staining, recognizing
the late phosphorylation of Ser 396/404 sites, starting at the age
of 12 months (Figure 1E, middle panel, and Figure S2), Gallyas
staining (Paired Helical Filament-specific silver impregnation)
was first noted at the age of 18 months (Figure 1E, second right
panel, and Figure S2), and Thioflavin S staining (b-pleated sheet
conformation) was detected at the age of 24 months (Figure 1E,
right panel, and Figure S2).
Biochemical characterization of mouse brain extracts con-
firmed age-dependent pathological changes in tau protein in
rTgTauEC mice (Figure 2). Western blot analysis of whole brain
extracts obtained from 12-, 18-, and 24-month-old rTgTauEC
and control mice confirmed human tau protein is expressed in
the brain and showed an age-dependent increase in total tau
and human tau (Figures 2A–2C). Quantification of tau hyper-
phosphorylation by western blot analysis of mouse brain
extracts from 12-, 18-, and 24-month-old rTgTauEC and control
micewas performed using phosphorylated tau antibodies AT180
(pT231), PHF1 (pS396/404), and CP13 (pS202) and normalized
to total tau levels (phosphorylation-independent). rTgTauEC
mice showed an age-dependent increase in all phosphorylated
epitopes (Figures 2D–2F). Twenty-four-month-old mouse brains
were subjected to sarkosyl extraction to biochemically confirm
the presence of insoluble tau aggregates. After sarkosyl extrac-
tion, a 64 kDa insoluble hyperphosphorylated tau species was
detected by immunoblotting in both rTg4510 and rTgTauEC
brains, but was absent in age-matched control brains when
analyzed using a total tau antibody (Figures 2G and 2H). In the
soluble fraction, the 55 kDa species of tau were also present,
similar to that seen in rTg4510 mice (Santacruz et al., 2005).
Human Tau Protein Propagates to Synaptically
Connected Brain Regions
The data above establish that human tau mRNA expression in
the MEC results in human tau protein expression and age-
dependent pathological accumulation in this region, as would
be expected. Restricting the transgene expression to the EC
also allowed us to investigate whether pathological tau changes
spread through neural circuits as predicted from pathological
studies of AD brain at different stages. The major output of the
EC is a large axonal projection called the perforant pathway
that carries input from EC-II and EC-III to the hippocampus,
terminating in the middle molecular layer of the DG (Steward,
1976; Van Hoesen and Pandya, 1975). We hypothesized that
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Figure 1. MEC-Restricted Expression of Human P301L-Mutated Tau Causes Progressive Tauopathy in EC Neurons
(A) rTgTauEC transgenic mice express human tauP301L under a tetracycline-responsive promoter (tetO) and the tetracycline transactivator (tTA) under the
neuropsin promoter.
(B and C) Low-magnification view of a medial horizontal section of rTgTauEC mouse brain stained with DAPI (B) and FISH showing human tau mRNA (C)
demonstrates the restriction of expression of human tauP301L to layer II of theMEC and the pre- and parasubiculum (Pre, Para). The EC andMEC are outlined with
a red dotted line. Note the lack of expression in the LEC, the subiculum (Sub), and the hippocampus including the DG, CA3, and CA1. There was no transgene
expression in age-matched controls (C, right panel; scale bar, 1 mm). Higher-magnification inset in (C) shows the white outline EC area (scale bar, 100 mm).
(D) Immunohistolabeling with phosphorylation-independent tau antibody 5A6 shows that tau protein is intensely expressed from 3months of age compared to an
age-matched control brain. Scale bar, 1 mm left and right panels, 200 mm in higher-magnification insets (center panels).
(E) Human tau-expressing neurons in the MEC develop progressive tau pathology beginning at 3 months of age, with Alz50-positive tau misfolding in the axon
terminal zone (molecular layer of the DG, left panel; scale bar, 200 mm). By 6 months of age, MEC neurons have Alz50-positive tau staining in their soma, and the
soma in this region increasingly accumulate pathological forms of tau with age, shown here bymarkers of later tau pathology including PHF1 (tau phosphorylated
at Ser396 and Ser404) starting from 12 months, Gallyas silver stain-positive neurons from 18 months, and Thioflavin S-positive neurofibrillary tangles by
24 months of age. Scale bar, 50 mm for all soma images.
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Propagation of Tau Pathology in a Model of ADtau expression in the MEC would lead to pathological tau accu-
mulation in a hierarchical fashion, first in the MEC, followed by
the DG, then the CA2/3 and CA1 regions, which are downstream
of the DG.
To test the possibility that misfolding of tau could be propa-
gated anterogradely along a neural network, areas that aresynaptically connected to the EC were investigated with histo-
logical stains of tau pathology (Figures 3A–3C; also see Table
S1). We find that neurons in the granular layer of the DG devel-
oped tau pathology several months after lesions appeared in
the MEC, with Alz50-positive and PHF1-positive soma appear-
ing in the DG at 18months andGallyas- and Thioflavin S-positiveNeuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc. 687
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Figure 2. Biochemical Characterization of Tau Pathology Reveals Age-Dependent Increase in Tau Hyperphosphorylation and Presence of
Sarkosyl-Insoluble Tau in rTgTauEC
(A–F) Representative immunoblots from western blot analysis of mouse brain extracts from 12-, 18-, and 24-month-old rTgTauEC and control mice. Antibodies
specific to phosphorylated tau (AT180 [pT231], PHF1 [pS396/404], and CP13 [pS202]), total tau, and human tau (htau) were used. Quantification of immunoblots
shows that rTgTauECmice present an age-dependent increase in total tau (B), human tau (results are expressed as percent of total tau expression at 24 months,
the highest expression point defined as 100%) (C), and phosphorylated epitopes (D–F) (n = 4 mice per group). A series of ultracentrifugation and extraction steps
were used to obtain sarkosyl-insoluble fractions of tau fromwhole brain of 24-month-old rTgTauEC, control (25 mg of protein loaded), and 18-month-old rTg4510
mice (5 mg of protein loaded) (positive control).
(G) Representative western blots of sarkosyl fractions are shown. Sarkosyl soluble (S) and insoluble fractions (I) were immunoblotted with total tau antibody
(phosphorylation-independent, Dako). Control mice did not show sarkosyl-insoluble tau. In contrast, immunoblotting of fractions from rTgTauEC mice revealed
sarkosyl-insoluble complexes of tau, of the same type as found in the brains of rTg4510 mice. A 64 kDa insoluble hyperphosphorylated tau species was detected
by immunoblotting in both rTg4510 and rTgTauEC brains but was absent in age-matched control brains when analyzed using total tau antibody. In the soluble
fraction, the 55 kDa species of tau was also present, similar to the species present in rTg4510 mice.
(H) Quantification of samples of sarkosyl fractions (n = 3 mice per group). Results are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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Propagation of Tau Pathology in a Model of ADsoma appearing at 24 months (Table S1; Figure S2). CA1 and
CA2/3 also develop pathological aggregates by 21 months of
age (Figures 3A–3C, middle and right panels). Western blot
analysis was used as an alternative approach to address if
human tau protein and tau hyperphosphorylation are spread to
downstream synaptically connected neurons. The levels of
human tau expression and tau phosphorylation were quantified
in the EC and hippocampus dissected from 17-month-old
rTgTauEC and controls. Human tau protein as well as PHF1688 Neuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc.tau could be detected in the EC and hippocampus of rTgTauEC
(Figures S3A and S3B), confirming the histological data showing
human tau protein present in the hippocampal formation.
This observation of human tau protein and pathology in areas
that largely do not express the human tau transgene indicates
that tau pathology spreads from cells expressing the transgene
to downstream neurons. Indeed, combined fluorescence in situ
hybridization (FISH) and immunofluorescent staining for both
human tau protein and Alz50 revealed neurons with human tau
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Figure 3. Tau Propagates through Neural Circuits
to mRNA-Negative Cells
(A–C) Several markers of pathological tau accumulation:
Alz50 (A), PHF1 (B), and Gallyas silver staining (C) appear
in brain regions synaptically connected to EC via the
perforant pathway, including DG, CA1, and CA2/3 (scale
bar, 50 mm).
(D and E) FISH for tau mRNA (green), coupled with im-
munolabeling (red) with Alz50 (D) or HT7 (E) shows
absence of mRNA in some cells containing the tau protein
(arrows). Scale bar, 20 mm.
(F) Colocalization of tau mRNA and Alz50-positive aggre-
gates was assessed by stereology at different ages and
compared to the total population of neurons carrying Alz50
aggregates. At 12 months of age, a third of the neurons
affected by the tau pathology were expressing the trans-
gene, while only 3% were positive for the MAPT gene at
24 months of age.
(G) FISH for MAPT mRNA [green in (E)] coupled with im-
munolabeling using HT7 [red in (E)] in the same EC
sections from 17-month-old animals was used to laser
capture three different populations of cells: (1) tau mRNA-
negative and human protein-negative neurons; (2) mRNA-
negative and human tau protein-positive neurons; and (3)
transgene mRNA-positive and human tau protein-positive
neurons. Total RNA was extracted and qPCR analysis of
the cDNA product was carried out using primers against
the transgenic human tau construct, showing that the
neurons that were human tau protein-positive and were
RNA-negative by FISH did not express the tau transgene,
confirming tau transmission to neurons that do not
express the human tau transgene. Results are expressed
as the mean ± SEM. *p < 0.001.
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tau transgene in the EC (Figures 3D and 3E), hippocampal fields
(Figures S3CandS3D), and anterior cingulate cortex (Figure S3E)
showing a dissociation between htau expression and human tau
protein accumulation. In the EC, quantification of human tau
mRNA and Alz50-positive cells revealed that only 33.3% of the
Alz50-positive neurons in EC expressed human tau mRNA at
12 months, indicating a spread of misfolded tau to neighboring
neurons within the EC without detectable transgene expression
(Figure 3F). By 24 months of age, an astonishing 97% of Alz50-Neuron 73, 685positive neurons (96.4% ± 6.45% SD; p <
0.001) did not have any detectable human trans-
gene expression, showing that the propagation
to neighboring cells increased with age (Fig-
ure 3F) and indicating that transgene expressing
neurons may be lost (as will be discussed later).
Alz50-positive aggregates were also found in
large numbers of neurons without detectable
transgene expression in the DG, anterior cingu-
late cortex, CA1, and CA3, all major targets of
the EC (Witter et al., 1988). Importantly, unlike
the anterior cingulate cortex, cortical areas
that showed limited transgene expression
outside of the EC, but do not receive direct input
from the EC, did not show any tau aggregation.
Moreover, the cerebellum, which expresseshuman P301L tau mRNA, did not develop any fibrillar accumula-
tion of htau in the soma.
These experiments with FISH showing human tau protein and
Alz50-positive aggregates in cells without detectable levels of
human tau mRNA confirm the transmission of human tau from
neuron to neuron and rule out the possibility that the transgene
promoter was nonspecifically expressing human tau in these
hippocampal neurons (i.e., becoming ‘‘leaky’’ in older animals).
To confirm that the absence of human tau mRNA in the FISH
experiments was not due to limited sensitivity of the technique,–697, February 23, 2012 ª2012 Elsevier Inc. 689
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cence with HT7 to label human tau protein in sections from
17-month-old animals. We then used laser capture microscopy
to capture three different populations of cells on an individual
cell-by-cell basis for analysis by qPCR: (1) neurons negative for
human tau mRNA and negative for human tau protein; (2)
neurons negative for human tau mRNA and positive for human
tau protein; (3) neurons positive for human tau mRNA and posi-
tive for human tau protein (Figure 3E). Total RNA was extracted
and qPCR analysis of the complementary DNA (cDNA) product
was carried out using primers against the transgenic human
tau construct. The qPCR data clearly show that the neurons
that were human tau protein-positive and RNA-negative by
FISH indeed did not express detectable levels of the tau trans-
gene (Figure 3G), in contrast to robust detection of tau mRNA
in neurons positive for tau mRNA by FISH. Taken together, these
data strongly suggest that the human tau protein may be under-
going neuron-to-neuron transmission.
Human Tau Seeds Mouse Tau Aggregation
The above experiments strongly suggest the spread of human
tau protein from neuron to neuron, which could cause seeding
of misfolding and aggregation of tau. It has been shown in cell
culture experiments that extracellular tau aggregates could be
internalized transmitting tau misfolding from the outside to the
inside of the cell, where these aggregates could seed fibril forma-
tion of recombinant tau monomer. Moreover, the same study
showed that tau aggregates were transferred between cocul-
tured cells (Frost et al., 2009). Another recent study reported
that brain extracts from neurofibrillary tangle-bearing mouse
brain injected in wild-type tau-expressing mice induces seeding
of tau fibrils in neurons (Clavaguera et al., 2009).
To determine whether mouse tau is recruited by human tau to
aggregate, we performed immunohistochemical analysis using
an antibody specific for mouse tau that revealed that mouse
tau indeed accumulates in the somatodendritic compartment
of MEC neurons of 24-month-old rTgTauEC mice (Figure 4A).
Age-matched control mice have diffuse axonal staining with
the mouse tau antibody, and tau knockout mice show no immu-
noreactivity, as expected. Human AD cases also have no
immunoreactivity to mouse tau, indicating that the observed
immunoreactivity is not due to human tau becoming reactive to
the mouse tau antibody during pathological changes. Results
from double labeling using Alz50 and mouse tau antibodies
showed that Alz50 and mouse tau staining colocalized in
neuronal cell bodies of the MEC, which is further evidence for
mouse tau recruitment into aggregates in the rTgTauEC mouse
model (Figure 4B). Immunoblotting using the mouse tau-specific
antibody also revealed that mouse tau increased with age in
rTgTauEC mice (Figure 4C), indicating that it may accumulate
in tangles. In confirmation of this idea, sarkosyl-insoluble
and -soluble fractions both contain endogenous mouse tau (Fig-
ure 4D). The specificity of themouse tau antibody was confirmed
by western blot analysis (Figure 4E), which revealed mouse tau
(mTau) reactivity in rTgTauEC and control mouse brain but not
in tau knockout mouse brain or human AD brain.
These data suggest that human tau enters neighboring cells
that do not have detectable levels of human tau transgene and690 Neuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc.transmits a misfolded state that recruits endogenous mouse
tau into the somatodendritic compartment, where it becomes
misfolded and contributes to tau aggregation.
Progressive Neurodegeneration and Gliosis
in rTgTauEC Neural Circuits
Tau pathology in rTgTauEC mice was first observed as Alz50
staining in the axon terminals from the perforant pathway arising
in EC-II terminating in themiddlemolecular layer of the DG (Table
S1). This has also been observed in AD patients (Hyman et al.,
1988) and suggests that conformationally abnormal tau is axo-
nally transported along the perforant pathway to presynaptic
axon terminals, or that the Alz50 epitope is generated first at
the axon terminals. We observed age-dependent degeneration
of axon terminals in rTgTauECmice (Figure 5A; for higher magni-
fication images, see Figure S2; for pathology progression, see
Table S1). Alz50 tau staining of misfolded tau in axon terminals
increased with age through 12 months (Figure 5A, second left
panel). At 18 months, the reactivity in axon terminals decreased
and staining in soma of the molecular layer of the DG became
more prominent, indicating the possibility that EC-II axons began
to degenerate and DG granular neurons took up the misfolded
protein (Figure 5A, middle panel). From 21 months of age, the
pattern of Alz50 reactivity in the middle molecular layer of the
DG changed from a clear layer to irregular patches in the axon
terminal zone (Figure 5A, right panels), similar to a pattern
observed in AD patients (Hyman et al., 1988).
Axonal degeneration was accompanied by gliosis in rTgTauEC
brain. rTgTauEC mice showed evidence of microglial activation
(Figures 5B and 5C) and astrogliosis (Figures 5D and 5E). At
24 months of age, Alz50-positive patches of axon terminals in
the middle molecular layer were surrounded by activated micro-
glia (Figure 5C), suggesting that axon terminals and their
synapses were degenerating in this area. Double labeling using
PHF1, phosphorylated tau antibody, and glial fibrillary acidic
protein (GFAP) antibody demonstrated reactive astrocytes that
were PHF1-positive at 24 months of age (Figure 5E). The tau
transgene is not expressed in glia, and there were no PHF1-posi-
tive astrocytes at earlier ages, indicating that human tau is likely
released from terminals and taken up by glia as the axons
degenerate.
The irregular patches of Alz50 staining of EC-II axon terminals
surrounded by activated microglia suggest that synapses are
lost in this region as axons degenerate. Previous studies have
shown that partial deafferentation of granule cells of the dentate
gyrus during normal aging was caused by a loss of axodendritic
synapses in the molecular layer, and a loss of axosomatic
synapses (Geinisman, 1979; Geinisman et al., 1977). In AD, early
hallmarks include the loss of synapses, and comparison of AD
patients to age-matched control individuals showed that the
density of synapses correlated strongly with cognitive impair-
ment, suggesting that loss of connections is associated with
the progression of the disease (DeKosky and Scheff, 1990;
Scheff and Price, 2006; Terry et al., 1991). Therefore, we as-
sessed two synaptic markers in the perforant pathway terminal
zone of rTgTauEC mice: synapsin-I, a marker of synaptic vesi-
cles, and PSD-95, a postsynaptic marker that has been reported
to decrease early in neurodegeneration (Zhao et al., 2006)
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Figure 4. Human Tau Protein Seeds Endogenous Mouse Tau Pathology
(A) Immunohistochemistry using a mouse-specific tau antibody (mTau) shows normal axonal distribution of mouse tau in control mice and somatodendritic
accumulation of mouse tau in rTgTauEC mice in the EC at 18 months of age. The mTau antibody showed no staining in tau knockout mice or human AD brain.
Scale bars, 100 mm.
(B) Double labeling using Alz50 and mouse tau antibodies shows that Alz50 and mouse tau staining colocalize in neuronal cell bodies. Scale bar, 20 mm.
(C) Whole brain extracts from rTgTauEC mice at different ages show an age-dependent increase in mouse tau. Representative blots are shown at the top, and
quantification is shown at the bottom (n = 4 mice per group). Results are expressed as the mean ± SEM. *p < 0.05.
(D) Sarkosyl-insoluble and -soluble fractions from whole brain of 18- and 24-month-old rTgTauEC probed using mTau revealed that sarkosyl-insoluble
and -soluble fractions both contain endogenous mouse tau.
(E) Immunoblotting of brain extracts using mTau confirmed its specificity, since it does not recognize protein in tau knockout brain or human AD brain.
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Propagation of Tau Pathology in a Model of AD(Figure 6A). We used array tomography to allow high-resolution,
quantitative measurement of synaptic densities. We found that
both pre- and postsynaptic densities were significantly reduced
in the middle third of the molecular layer at 24 months of age in
tau-expressing transgenic mice (Figure 6B).
To estimate neuronal loss, neuronal counts in the EC and
hippocampal subareas were performed on transgenic and
control animals at 21 and 24 months of age (n = 3 to 4 animals
per group), using stereological estimations of cresyl violet-labeled neuronal nuclei. Neurons were identified by their
morphology. In rTgTauEC mice, significant neuronal loss was
detected at 24 months of age in the areas of transgene expres-
sion, EC-II, and parasubiculum, compared to the average neuron
number in age-matched control brains (Figure 6C). We observed
a 42% decrease in neuron density in EC-II. We did not observe
significant neuronal loss up to 21 months of age. Quantification
by stereological counts showed that 47% of all neurons in the
EC-II were Alz50-positive at 12 months of age; this figureNeuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc. 691
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Figure 5. Axon Terminals Degenerate Progres-
sively in the Terminal Zone of EC-II Axons
(A) The terminal zone of axonal projections from the layer II
MEC neurons with the granular layer (gl) and the middle
molecular layers (mml) that express the human tau trans-
gene developed early accumulation of misfolded tau
(Alz50 staining, which intensified up to 12 months of age.
At 18 months, the terminal staining with Alz50 became
fainter with DG neurons in the granular cell layer becoming
more prominently stained. At 21 and 24 months, Alz50
staining in the terminal zone was patchy, indicating
degeneration of Alz50-containing axons (scale bar,
100 mm).
(B) Concomitant with this axonal degeneration, we
observed increased microglial activation (Iba1 staining) at
24 months of age in rTgTauEC mice in the molecular layer
of the DG. Scale bars, 50 mm (left panel), 20 mm (right
panel).
(C) Double immuno-histolabeling with Alz50 and Iba1
shows that the patches of Alz50 staining of the axon
terminals in the middle molecular layer of the DG are
surrounded by activated microglia (shown in higher
magnification in the inset). Scale bars, 50 mm (left panel),
20 mm (right panel).
(D) GFAP-labeled astrocytes are more prevalent in
rTgTauEC brain than controls. Scale bars, 50 mm.
(E) Colocalization of GFAP- and PHF1-positive aggregates
indicate uptake of tau by astrocytes. Scale bars, 20 mm.
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Propagation of Tau Pathology in a Model of ADdropped to approximately 10% at 24 months of age (Figure 6D),
as some neurons died.
We hypothesize that the observed age-associated neurode-
generation is due to the age-dependent toxicity of tau that is
pathologically mislocalized to the soma, hyperphosphorylated,
and aggregated, similar to observations in human AD brain. To
formally exclude the possibility that axonal degeneration and
neuronal loss at 24 months are not due to increased transgene
expression at later ages, we quantified the percentage of
neurons expressing the human tau transgene. Stereological
counts of human tau-expressing neurons labeled with FISH
show that approximately 12% of neurons (12.4% ± 1.69%
SEM) in EC-II expressed the transgene at 3 months of age
(Figures 6E and 6F). This number was unchanged at 12 months
(13.21% ± 0.86% SEM; p = 0.366) and 18 months of age
(12.18% ± 1.96 SEM; p = 0.481), showing that only a portion of
neurons in the EC-II expressed the human tau transgene. At
24 months of age, only 4% (3.71% ± 0.84% SEM) of the
neurons expressed the transgene (Figures 1C and 1D) (p <
0.005). The pattern of human tau protein expression also
changes as the animals age. There is a significant reduction in
the human tau immunofluorescence staining of the EC at
24months, and the cell bodies of the DG neurons become immu-
noreactive for human tau, suggesting that the protein is being
transmitted (Figure S4).
Together, these data indicate that neurodegeneration begins
in this model of early AD with degeneration of axon terminals fol-
lowed by loss of synapses and neurons. Further, the cell loss
observed at 24 months exceeds the number of neurons that
were expressing the transgene, suggesting that neurons that
develop tau pathology without expressing the transgene might
also be lost.692 Neuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc.DISCUSSION
To understand the sequence of events from expression of path-
ological tau in the EC to the development of widespread cortical
involvement, we recreated an early stage of AD neurofibrillary
pathology in transgenic mice to investigate how, starting in the
entorhinal area, tau pathology leads to neural system dysfunc-
tion. We observed two important consequences of the formation
of tangles in the EC: (1) spreading of the pathology to down-
stream connected neurons despite regional and cellular restric-
tion of transgene expression, and (2) evidence favoring very slow
synaptic, then axonal, then somatic degeneration associated
with accumulation of misfolded tau.
Recent data suggest that intracellular protein aggregates of
tau have the capacity to seed aggregation of native tau proteins
andmight propagate their misfolded state in a prion-like manner.
This transmission has first been described to occur inside cells,
since incorrectly folded tau proteins convert to an aggregate-
prone state acting as a nucleus that recruits additional taumono-
mers (de Calignon et al., 2010; Iliev et al., 2006; Mocanu et al.,
2008). In cell culture experiments (Frost et al., 2009), extracellular
tau aggregates could enter cells and trigger tau fibrillization. In
living mouse brain, intracortical injections of tau aggregates
seed tau fibrillization in neurons carrying the human transgene
(Clavaguera et al., 2009). Here, we found that in aged rTgTauEC
mice, human tau protein is present in neurons that do not have
detectable levels of human tau mRNA, suggesting that trans-
neuronal propagation of tau occurs. This idea is also supported
by our data showing that (1) in EC-II, the number of transgene-
expressing neurons decreases in older age, correlating with
neuronal loss, while (2) the proportion of transgene-negative
Alz50-positive neurons robustly increases with age, suggesting
A B
C
E F
D
Figure 6. Synaptic Loss in the Target Zone
of the Perforant Pathway and Loss of EC-II
Neurons in rTgTauEC Mice
(A and B) Array tomography using synapsin I
(green) and PSD95 (red) to label pre- and post-
synaptic structures in themiddlemolecular layer of
the DG (scale bar, 2 mm) shows pre- and post-
synaptic loss at 24 months of age in the middle
molecular layer of the DG, indicating loss of
synapses between EC-II neurons and DG neurons.
(C) Numbers of neurons were estimated by stere-
ology for different areas of the brain (PreS, pre-
subiculum; ParaS, parasubiculum). Significant
neuronal loss was detected at 24 months of age in
EC-II and the parasubiculum compared to age-
matched control brain.
(D) Similar stereological quantification showed
that 47% of neurons in the EC were Alz50-positive
at 12 months of age and 10% were Alz50-posi-
tive at 24 months of age.
(E and F) Levels of transgene expression. Loss of
neurons could not be explained by an increase in
transgene expression with age, since the level of
transgene expression assessed by stereological
counts of tau mRNA-positive neurons labeled with
FISH showed that the level of transgene expres-
sion in MEC did not change from 3 to 18 months of
age and significantly decreased at 24 months
(scale bar, 100 mm). Results are expressed as the
mean ± SEM. *p < 0.05.
Neuron
Propagation of Tau Pathology in a Model of ADthat the remaining Alz50-positive neurons were secondarily
affected by transneuronal transfer. It has been reported that glial
tau pathology occurs in tauopathies (Ballatore et al., 2007; Chin
and Goldman, 1996) and in AD (Nakano et al., 1992; Nishimura
et al., 1995; Papasozomenos, 1989a, 1989b), where tau inclu-
sions can be found in astrocytes and oligodendrocytes. The
presence of human tau protein in GFAP-positive astrocytes in
rTgTauEC mice suggests that release of tau from neurons and
uptake by glia also takes place in this model.
The specificity of the neuropsin-driven transactivator for EC
and related structures was demonstrated by FISH, qPCR,
immunostaining, and western blot analysis of rTgTauEC mice.
Moreover, the parental P301L mice without the transactivator
transgene showed levels of human tau protein or mRNA (Fig-
ure S1) below detection thresholds, in accord with a recent
observation that the ‘‘tau alone’’ parental line expresses <2%
of the levels of rTg4510mice and does not develop any tau path-
ological alterations with age (Barten et al., 2011).Neuron 73, 685–697,Taken together, the data presented in
this study indicate that, in rTgTauEC
mice, tau was not only transferred to
neighboring cells, but also to synaptically
connected neurons, which suggests that
tau—or a particular species of tau, such
as hyperphosphorylated tau, misfolded
tau, or a fragment of tau—may have
been released at the synapse. In the
DG, CA regions, and cingulate cortex,
we found neurons that do not havedetectable human taumRNA at any of the ages examined, which
accumulated tau immunoreactive species (recognized by
multiple antibodies) at advanced ages (21 and 24 months). In
parallel to our study, a recent report described a mouse model
of mutant amyloid precursor protein expressed predominantly
in the EC that used the same promoter as that of rTgTauEC
mice. Progression of Ab deposition to the hippocampus and
cingulate cortex was also reported (Harris et al., 2010). These
data suggest that misfolded tau and Ab share properties that
allow propagation through the extracellular space to disrupt
neuronal systems.
Our data support the idea that tau, when accumulated in the
terminal zones, induces synaptic destruction. We cannot distin-
guish between the possibilities that misfolded axonal tau
induces dying back terminal degeneration, or that release of
tau is synaptotoxic. It is not clear how, or if, misfolded tau gets
released and/or taken up by neurons, but the presence of
increased tau cerebrospinal fluid levels after injury is consistentFebruary 23, 2012 ª2012 Elsevier Inc. 693
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1995). In rTgTauEC mice, propagation seems more tightly linked
to the time frame when axons are dying back (21–24 months)
than when Alz50-positive tau can be detected in axon terminals
(3 months), but this does not preclude the possibility that some
tau is released and taken up at earlier ages, even under normal
physiological circumstances.
Interestingly, by using a specific mouse tau antibody, we also
show evidence that endogenous mouse tau accumulates in the
somatodendritic compartment of EC neurons, where it coaggre-
gates with human tau. Furthermore, we also report that mouse
tau can be detected in both the sarkosyl-soluble and -insoluble
fractions, suggesting that misfolded human tau can recruit
endogenous mouse tau to aggregate.
If the propagation of AD tangle pathology fromBraak stage I to
VI entails, to some extent, the type of neuronal system propaga-
tion events described here, several critical questions remain. (1)
Why are some neuronal populations protected from developing
tangles despite being anatomically strongly connected to
neuronal populations that do develop tangles? (2) Does tau
need to emerge into the extracellular space where it is potentially
available to therapies such as immunotherapy, or might it be
released from the cytoplasm, yet remain sequestered within
membrane-bound compartments such as exosomes? (3) Which
species of tau are responsible for transferring the aggregated
state to nonexpressing cells? (4) Is the tau that is capable of initi-
ating misfolded aggregates in downstream cells an aggregated
form or a consequence of a unique posttranslational modifica-
tion such as phosphorylation, acetylation, glycosylation, or trun-
cation? Understanding these issues may help inform therapeutic
approaches that have promise to slow the progression of AD.
EXPERIMENTAL PROCEDURES
Animals
We generated the line of transgenic animals (called rTgTauEC [reversible tau
restricted to EC]) by crossing FVB-Tg(tetO-TauP301L)4510 mice (Santacruz
et al., 2005) with a transgenic mouse line on a C57BL/6 genetic background
expressing tet transactivator under the control of the neuropsin promoter
(developed at The Scripps Research Institute [Yasuda and Mayford, 2006]).
Only F1 offspring were used as experimental animals, ensuring a uniform
50:50 mix of FVB and C57BL/6 genetic background. The human Tau gene
with the P301L mutation in rTg4510 mice is downstream of a tetracycline-
operon responsive element and requires the presence of the tet transactivator
(Gossen and Bujard, 1992). Since the tet transactivator is downstream of the
promoter of neuropsin, human tauP301L expression is restricted to EC-II. Mice
with both the activator and responder transgenes are abbreviated rTgTauEC.
Age-matched littermates expressing only the activator transgene and the
responder transgenewere used as controls.Micewere screenedbyPCRusing
the primer pairs 50-ACCTGGACATGCTGTGATAA-30and 50-TGCTCCCATT
CATCAGTTCC-30 for activator transgenes and 50-TGA ACC AGG ATG GCT
GAGCC-30 and50-TTGTCATCGCTTCCAGTCCCCG-30 for responder trans-
genes. Each of the eight age groups studied (3, 6, 9, 12, 15, 18, 21, 24 months)
contained transgenic and control animals. A total of 183 animals were used for
this study, including 97 transgenic and 86 control animals.
All animalexperimentswereperformed inaccordancewithnational guidelines
(National Institutes of Health) and approved byMassachusettsGeneral Hospital
and McLaughlin Institute Institutional Animal Care and Use Committees.
Human Subject
Formalin-fixed, paraffin-embedded tissue specimens and frozen tissue from
the temporal association isocortex (Brodmann area 38) of one patient with694 Neuron 73, 685–697, February 23, 2012 ª2012 Elsevier Inc.ADwas obtained from theMassachusetts Alzheimer Disease Research Center
Brain Bank. The study subject and their next of kin gave written informed
consent for the brain donation, and the Massachusetts General Hospital Insti-
tutional Review Board approved the study protocol. The subject fulfilled the
National Institute of Neurological and Communicative Disorders Alzheimer’s
Disease and Related Disorders Association criteria for probable AD and the
National Institute on Aging-Reagan criteria for high likelihood of AD.
Stereology and Immunocytochemistry
TheanimalswereeuthanizedbyCO2asphyxiationand thebrainsharvested, fixed
in 4%paraformaldehyde containing 15% glycerol cryoprotectant for 2 to 3 days,
then either sectioned or stored at 4C in a 20%sucrose solution. The brainswere
frozen and serial horizontal sections 40 mm thick were cut on a freezing sliding
microtome. Groups of every 10 sections were used to characterize each brain.
An unbiased stereologic counting method was used to determine the
number of neurons per region of the brain (Hyman et al., 1998). The optical
dissector technique was used in a similar fashion to previously described
work in transgenic mice (Irizarry et al., 1997). The image analysis system
NewCAST (stereology module for VIS; Visiopharm Integration System ver.
2.12.3.0, Denmark), mounted on an upright Olympus BX51 microscope
(Olympus, Denmark) with an integrated motorized stage (PRIOR-Proscan II,
Prior Scientific, Rockland, MA) was used to outline regions, sample, and count.
Counting frames of size 21.8 mm3 21.8 mm, and step length from 100 mm to
200 mm were selected to count >200 neurons per animal. The different brain
regions were defined using the atlas developed by Franklin and Paxinos
(2007). The differentiation between theMECand LECwasmade using the atlas
mentioned above and the mapping of van Groen (2001).
Standard immunofluorescence techniques were used to label Tau epitopes.
Endogenous peroxidase activity was quenched for 30 min in H2O2. After
blocking in 5% milk for 1 hr, the appropriate primary antibody was applied,
and sections were incubated overnight at 4C. Sections were subsequently
washed in Tris-buffered saline (TBS) to remove excess primary antibody.
Sections were incubated in the appropriate secondary antibody for 1 hr at
room temperature. After serial washes in TBS, slides were developed with di-
aminobenzidine substrate by using the avidin-biotin horseradish peroxidase
system (Vector Laboratories). Fluorescent CY3-labeled secondary antibody
(Invitrogen) was used to reveal 5A6.
The antibodies with 5A6 (generated by G.V. Johnson, 1997; 1:1,000), HT7
(Thermo Scientific; 1:1,000), and TauY9 (Enzo Life Sciences; 1:1,000) were
used to specifically detect human tau; the conformation-specific Alz50 antibody
(courtesy of Peter Davies, Albert Einstein College of Medicine; 1:50) and
phosphorylated 396/404 tau PHF1 (courtesy of Peter Davies; 1:500) antibodies
were used to detect pretangle stages. Fluorescent CY3-labeled secondary
antibody (Invitrogen) was used to reveal HT7, and nonfluorescent biotinylated
secondary antibodies revealed by diaminobenzidine were used to detect Alz50
and PHF1. The antibody Iba1 (Wako, 1:1,000) was used to reveal microglia.
Activated astrocytes were labeled using the GFAP antibody (Sigma, 1:1,000).
mTau is a polyclonal rabbit antibody that was generated by Dr. Naruhiko
Sahara. Briefly, mTau was raised against a mouse tau epitope, which is absent
in the human tau sequence and corresponds to amino acid residues 118–131
(SKDRTGNDEKKAKG). The antibody was characterized by western blot anal-
ysis and immunohistochemistry for sensitivity and specificity and did not
recognize any unspecific proteins in tau knockout (KO) mice or in human brain.
Tau KO mice, which have a targeted disruption of exon 1 of tau (Tucker et al.,
2001), were used for the characterization of the mTau antibody. Tau KO mice
were bred with C57Bl/6 mice to produce tau KO heterozygote mice also used
in the antibody characterization.
Gallyas silver staining was performed on brain sections according to
previous description (Gallyas, 1971). Thioflavin S staining was performed by
leaving the mounted sections for 8 min in a solution of 0.05% Thioflavin S in
50% ethanol (EtOH), rinsed in ethanol 100%, then water (Sun et al., 2002).
Images for figures were collected on an upright Olympus BX51 microscope
(Olympus America, Center Valley, PA).
In Situ Hybridization and Riboprobe Generation
Colorimetric in situ hybridization and riboprobe generation were performed as
previously described (Schaeren-Wiemers and Gerfin-Moser, 1993). FISH with
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(Price et al., 2002). Riboprobe templates were generated by RT-PCR from
mouse and human brain tissue and correspond to the 30 untranslated regions
of mouse Mapt (NM_001038609.1; nucleotides 1606–2588) and human Mapt
(NM_016835; nucleotides 2773–3602).
Laser Capture Microdissection and qPCR Analysis following FISH
and Immunofluorescence
Cryosections (10 mm) of snap-frozen brains from 24-month-old rTgTauEC
mice were collected on microscopy slides (Gold Seal Rite-On Micro Slides,
Portsmouth, NH). Following FISH, each tissue section was fixed in 70%
EtOH for 40 s, rinsed with RNase-free PBS, incubated with the human
tau-specific HT7 antibody in PBS for 10 min, rinsed with PBS, incubated
with Alexa 488 goat anti-mouse immunoglobulin G (IgG) (Invitrogen) in PBS
for 10 min, rinsed with PBS followed by dehydration in increasingly concen-
trated EtOH 70%–100% into xylene. Different populations of cells were
captured after FISH and immunofluorescence that can be divided into three
groups: (1) tau mRNA-negative and human protein negative neurons; (2)
mRNA-negative and human tau protein-positive neurons; and (3) transgene
mRNA-positive and human tau protein-positive neurons. Approximately 500
cells from EC-II and the DG were captured per group onto separate polyeth-
ylene collecting caps (Macro Cap, Arcturus, MDS Analytical Technologies,
Sunnyvale, CA). Total RNA was extracted using the Arcturus PicoPure RNA
isolation kit per the manufacturer’s instructions. Samples were eluted in
14 ml. RNA samples were assayed for quality with an Agilent 6000 Bioanalyzer
and a Nanodrop spectrophotometer. Reverse transcription was carried out on
all RNA samples (Superscript II, Invitrogen) and random hexamers. qPCR anal-
ysis (on Bio-Rad iCycler) of the cDNA product was carried out using primers
against the transgenic human tau construct (50-CCC AAT CAC TGC CTA
TAC CC-30 and 50-CCA CGA GAA TGC GAA GGA-30), mouse tau exon 7
(50-AGC CCT AAG ACT CCT CCA-30 and 50-TGC TGT AGC CGC TTC GTT
CT-30), and glyceraldehyde-3-phosphate dehydrogenase (50-TGG TGA AGC
AGGCAT CTG AG-30 and 50-TGC TGT TGA AGT CGC AGG AG-30). Triplicates
of cDNA samples were added to a 25 ml reaction containing 12.5 ml SYBR
green Mastermix (Applied Biotechnology). For the standard curve, we
subcloned cDNA amplicons generated using the qPCR primers in the
pcDNA 3.1 vector system (Invitrogen) according to the manufacturer’s instruc-
tions. After verifying the respective specificities of the cDNA clones by
sequencing, these were used to generate individual standard curves, thus al-
lowing for calculation of molarity and number of mRNA molecules in the
samples. Finally, the respective tau mRNA levels were normalized to murine
tau mRNA levels.
Western Blot Analysis
Animals were sacrificed by decapitation, the brains were extracted, and either
the brain or hippocampi and EC were dissected. Tissue was homogenized in
radio-immunoprecipitation assay buffer (Sigma) supplemented with a cocktail
of protease and phosphatase inhibitors (Roche). Samples were homogenized
using a Polytron and stored at 80C. The materials for SDS-PAGE were ob-
tained from Invitrogen (NuPAGE system). Protein lysateswere boiled in sample
buffer consisting of lithium dodecyl sulfate sample buffer and reducing agent
and resolved on 4%–12% Bis-Tris polyacrylamide precast gels in a 3-(n-mor-
pholino)propanesulfonic acid-SDS running buffer containing antioxidant. For
most analyses, 30 mg/lane were loaded, unless indicated otherwise. Gels
were transferred onto NitrocelluloseMembranes Protran (Whatman) in transfer
buffer containing 20% methanol. Blots were blocked in Odyssey blocking
buffer (Li-Cor biosciences), followed by incubation with primary antibodies
(b -actin [Sigma; 1:10,000]; Total Tau [Dako; 1:10,000], HT7 [1:5,000], TauY9
[1;1,1000], mTau [Naruhiko Sahara; 1:5,000], AT180 [pT231, Thermo Scien-
tific; 1:1,000], PHF1 [courtesy of Peter Davies; 1:5,000], CP13 [courtesy of
Peter Davies, 1:1,000], and DA9 [courtesy of Peter Davies; 1: 10,000]) and
detected with anti-mouse or anti-rabbit IgG conjugated to IRDye 680 or 800
(Li-Cor Biosciences; 1:10,000). Densitometric and MW analyses were per-
formed using ImageJ software (National Institutes of Health). Band density
values were normalized to b-actin or total tau levels when tau phosphorylation
levels were analyzed. Mean band densities for samples from rTgTauEC mice
were normalized to corresponding samples from control mice.Sarkosyl Insolubility Assay
Purification of sarkosyl-insoluble tau was performed as previously described
(Hasegawa et al., 2007) with slight modifications. Briefly, whole frozen brains
of 24- and 18-month-old rTgTauEC (n = 3), control (n = 3), and 18-month-old
rTg4510 (n = 1) mice were homogenized by polytron in 10 volumes of buffer
H (10 mM Tris-HCl [pH 7.5] containing 0.8M NaCl, 1 mM EGTA, and 1 mM di-
thiothreitol) and spun at 100,0003 g for 30 min at 4C. Another 2 ml of buffer H
was added to the pellet and the samples were homogenized again by polytron,
incubated in 1% Triton X-100 at 37C for 30 min. Following the incubation, the
samples were spun at 100,000 3 g for 30 min at 4C, the pellet was homoge-
nized by polytron on 1 ml of buffer H and was then incubated in 1% sarkosyl at
37C for 30 min and spun at 100,000 3 g for 30 min at 4C. The supernatant
was then collected (sarkosyl-soluble fraction). Detergent-insoluble pellets
were extracted in 100 ml of urea buffer (8 M urea, 50 mM Tris-HCl [pH 7.5]),
sonicated, and spun at 100,000 3 g for 30 min at 4C. The supernatant was
then collected (sarkosyl-insoluble fraction). The protein concentration of
extracts was determined by BCA assay (Thermo Scientific), and either
25 mg/lane (rTgTauEC) or 5 mg/lane (rTg4510) were loaded were loaded.
Sarkosyl-insoluble and -soluble fractions were run on SDS-PAGE gels (4%–
20%), transferred to nitrocellulose membranes, and probed with total tau
DA9 (epitope: aa 112–129) mouse monoclonal antibody (courtesy of Peter
Davies; 1:1,000). The DA9 antibody recognizes both human and mouse tau
proteins and was generated against human tau preparations (Tremblay
et al., 2010).
Array Tomography
Tissue blocks from the DG of 21- and 24-month-old rTgTauEC (n = 3 at
21months, n = 3 at 24months) mice and littermate controls (n = 5 at 21months,
n = 3 at 24 months) were prepared for array tomography as described previ-
ously (Koffie et al., 2009; Micheva and Smith, 2007). Briefly, mice were sacri-
ficed using carbon dioxide, brains were removed, and small blocks containing
DG were dissected, fixed in 4% paraformaldehyde with 2.5% sucrose in PBS
for 2 hr, dehydrated, and embedded in LR White resin (Electron Microscopy
Sciences, Hatfield, PA). Ribbons of ultrathin sections (70 nm) were collected
on slides and stained with antibodies to synapsin I (rabbit polyclonal Ab1543
Millipore, Billerica, MA), PSD95 (goat polyclonal Abcam Ab12093, Cambridge,
MA), and secondary donkey anti-rabbit Cy3 and donkey anti-goat Cy5 (Jack-
son ImmunoResearch, West Grove, PA) counterstained with a fluorescent
Nissl counterstain (NeuroTrace blue, N21479, Invitrogen, Carlsbad, CA).
Images of the same area of themiddlemolecular layer of the DGwere obtained
on 7–11 serial sections in two different sample sites per animal using a Leica
TCS SL confocal system (Leica Microsystems Bannockburn, IL). Images
were made into stacks and aligned using ImageJ software. Three to six crop
boxes were chosen in each stack in a region free of nuclei. Each crop was
analyzed using the watershed program (generously provided by B. Busse
and Stephen Smith) to count puncta that are present in more than one consec-
utive image in the stack to remove noise.
Data were analyzed using JMP (SAS Institute, Cary, NC). Normality of the
data was tested using a Shapiro-Wilks test. One-way analysis of variance
was used to compare means of the different genotypes. Data are presented
as the mean ± SEM.
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